Johnson & Johnson Treasury Stock, Value, Acquired, Cost Method
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- Johnson & Johnson treasury stock, value, acquired, cost method for the quarter ending 2026-06-28 was $219.00M.
- Johnson & Johnson treasury stock, value, acquired, cost method for the quarter ending 2025-12-28 was $1.92B, a 647.86% increase year-over-year.
- Johnson & Johnson treasury stock, value, acquired, cost method for the quarter ending 2025-09-28 was $1.90B, a 253.25% increase year-over-year.
- Johnson & Johnson treasury stock, value, acquired, cost method for the quarter ending 2025-06-29 was -$2.00M, a 101.47% decline year-over-year.
- Johnson & Johnson treasury stock, value, acquired, cost method for fiscal 2025 was $5.95B, a 147.32% increase from fiscal 2024.
- Johnson & Johnson treasury stock, value, acquired, cost method for fiscal 2024 was $2.41B, a 52.37% decline from fiscal 2023.
- Johnson & Johnson treasury stock, value, acquired, cost method for fiscal 2023 was $5.05B, a 16.26% decline from fiscal 2023.
- Johnson & Johnson treasury stock, value, acquired, cost method for fiscal 2023 was $6.04B, a 74.62% increase from fiscal 2022.
| Period end | Treasury Stock, Value, Acquired, Cost Method 3 month | Treasury Stock, Value, Acquired, Cost Method 12 month |
|---|---|---|
| 2026-06-28 | $219.00M 10-Q · filed 2026-07-23 | |
| 2025-12-28 | $1.92B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $5.95B 10-K · filed 2026-02-11 |
| 2025-09-28 | $1.90B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-22 | $4.29B derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-06-29 | -$2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | $2.92B derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-03-30 | $2.13B 10-Q · filed 2026-04-22 | $3.06B derived: sum of 4 quarters · filed 2026-04-22 |
| 2024-12-29 | $257.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $2.41B 10-K · filed 2026-02-11 |
| 2024-09-29 | $539.00M 10-Q · filed 2025-10-22 | $2.37B derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $136.00M 10-Q · filed 2025-07-24 | $2.75B derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $1.48B 10-Q · filed 2025-04-23 | $2.99B derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $216.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $5.05B 10-K · filed 2026-02-11 |
| 2023-10-01 | $920.00M 10-Q · filed 2024-10-23 | $6.16B derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-07-02 | $381.00M 10-Q · filed 2024-07-25 | $7.40B derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-04-02 | $3.54B 10-Q · filed 2024-05-01 | $8.00B derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-01-01 | $1.32B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $6.04B 10-K · filed 2025-02-13 |
| 2022-10-02 | $2.17B 10-Q · filed 2023-10-27 | $5.71B derived: sum of 4 quarters · filed 2024-02-16 |
| 2022-07-03 | $973.00M 10-Q · filed 2023-07-31 | $3.94B derived: sum of 4 quarters · filed 2024-02-16 |
| 2022-04-03 | $1.58B 10-Q · filed 2023-04-28 | $3.60B derived: sum of 4 quarters · filed 2024-02-16 |
| 2022-01-02 | $996.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-16 | $3.46B 10-K · filed 2024-02-16 |
| 2021-10-03 | $391.00M 10-Q · filed 2022-10-27 | $2.78B derived: sum of 4 quarters · filed 2023-02-16 |
| 2021-07-04 | $631.00M 10-Q · filed 2022-07-29 | $2.87B derived: sum of 4 quarters · filed 2023-02-16 |
| 2021-04-04 | $1.44B 10-Q · filed 2022-04-29 | $2.95B derived: sum of 4 quarters · filed 2023-02-16 |
| 2021-01-03 | $321.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | $3.22B 10-K · filed 2023-02-16 |
| 2020-09-27 | $483.00M 10-Q · filed 2021-10-29 | $3.33B derived: sum of 4 quarters · filed 2022-02-17 |
| 2020-06-28 | $706.00M 10-Q · filed 2021-07-29 | $4.47B derived: sum of 4 quarters · filed 2022-02-17 |
| 2020-03-29 | $1.71B 10-Q · filed 2021-04-30 | $6.25B derived: sum of 4 quarters · filed 2022-02-17 |
| 2019-12-29 | $426.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $6.75B 10-K · filed 2022-02-17 |
| 2019-09-29 | $1.63B 10-Q · filed 2020-10-23 | $10.13B derived: sum of 4 quarters · filed 2021-02-22 |
| 2019-06-30 | $2.49B 10-Q · filed 2020-07-24 | $8.97B derived: sum of 4 quarters · filed 2021-02-22 |
| 2019-03-31 | $2.21B 10-Q · filed 2020-04-29 | $6.63B derived: sum of 4 quarters · filed 2021-02-22 |
| 2018-12-30 | $3.81B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-22 | $5.87B 10-K · filed 2021-02-22 |
| 2018-09-30 | $471.00M 10-Q · filed 2019-10-28 | |
| 2018-07-01 | $145.00M 10-Q · filed 2019-07-29 | |
| 2018-04-01 | $1.44B 10-Q · filed 2019-05-01 | |
| 2017-12-31 | $6.36B 10-K · filed 2020-02-18 | |
| 2017-01-01 | $8.98B 10-K · filed 2019-02-20 | |
| 2016-01-03 | $5.29B 10-K · filed 2018-02-21 | |
| 2014-12-28 | $7.12B 10-K · filed 2017-02-27 | |
| 2013-12-29 | $3.54B 10-K · filed 2016-02-24 | |
| 2012-12-30 | $12.92B 10-K · filed 2015-02-24 | |
| 2012-01-01 | $2.52B 10-K · filed 2014-02-21 | |
| 2011-01-02 | $2.80B 10-K · filed 2013-02-22 | |
| 2010-01-03 | $2.13B 10-K · filed 2012-02-23 | |
| 2008-12-28 | -$6.65B 10-K · filed 2011-02-25 | |
| 2007-12-30 | -$5.61B 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |